Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Cited by 85 Publications

Cancer Cell, 2013, 23(6):839-52

PubMed: 23684459 ( click the link to review the publication )

Cell, 2012, 149(3):656-70

PubMed: 22920938 ( click the link to review the publication )

Cancer Lett, 2019, 447:93-104

PubMed: 30660646 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(2):356-363

PubMed: 30446585 ( click the link to review the publication )

Front Oncol, 2019, 9:422

PubMed: 31192127 ( click the link to review the publication )

Mol Med Rep, 2019, 20(1):33-40

PubMed: 31115502 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):739

PubMed: 29970892 ( click the link to review the publication )

Front Aging Neurosci, 2018, 10:378

PubMed: 30515090 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(11):1219-1229

PubMed: 30265530 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(8):748-756

PubMed: 29961813 ( click the link to review the publication )

BMC Neurosci, 2018, 19(1):52

PubMed: 30189852 ( click the link to review the publication )

Transl Cancer Res, 2018, 7(6):1548-1560

PubMed: 30761266 ( click the link to review the publication )

Am J Pathol, 2017, 187(8):1736-1749

PubMed: 28627412 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169585

PubMed: 28081222 ( click the link to review the publication )

PLoS One, 2017, 12(3):e0173473

PubMed: 28291820 ( click the link to review the publication )

Biotechnol Lett, 2017, 39(9):1343-1349

PubMed: 28597147 ( click the link to review the publication )

Sci Rep, 2017, 7:42062

PubMed: 28165023 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(6):3130-3145

PubMed: 27980063 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:305-313

PubMed: 27665476 ( click the link to review the publication )

Exp Cell Res, 2016, 340(1):81-90

PubMed: 26712518 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 479(1):54-60

PubMed: 27614310 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(4):1170-6

PubMed: 27073162 ( click the link to review the publication )
J Mol Neurosci, 2016, 59(4):567-78

PubMed: 27412469 ( click the link to review the publication )

Anticancer Res, 2016, 36(11):5849-5858

PubMed: 27793908 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):1025-33

PubMed: 26269112 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.04.015

PubMed: 25934232 ( click the link to review the publication )

Mol Cell Biochem, 2015, 398(1-2):105-13

PubMed: 25223639 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3244-2

PubMed: 25697899 ( click the link to review the publication )

Oncoscience, 2015,

PubMed: ( click the link to review the publication )

Oncoscience, 2015, 10.1155/2015/8332

PubMed: ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.184.

PubMed: 24998847 ( click the link to review the publication )

FASEB J, 2014, 27(7):2584-99

PubMed: 23507869 ( click the link to review the publication )

Cardiovasc Diabetol, 2014, 35(7):450-4

PubMed: 24836459 ( click the link to review the publication )

Carcinogenesis, 2014, 35(10):2232-43

PubMed: 24942865 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(9):1851-64

PubMed: 24769208 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 450(1):646-51

PubMed: 24946212 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):362-7

PubMed: 25264192 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(1):72-8

PubMed: 25152399 ( click the link to review the publication )
Vet J, 2014, 201(1):83-90

PubMed: 24881508 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Rostock University, 2014, Lange F

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Lett, 2013, 336(2):319-24

PubMed: 23528835 ( click the link to review the publication )

Gynecol Oncol, 2013, 131(1):207-12

PubMed: 23877012 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1831(8):1322-34

PubMed: 23707264 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1828(5):1384-9

PubMed: 23376656 ( click the link to review the publication )

J Biol Chem, 2013, 288(31):22836-48

PubMed: 23788636 ( click the link to review the publication )

Mol Pharmacol, 2013, 84(4):562-71

PubMed: 23877009 ( click the link to review the publication )

Biochimie, 2013, 101:50-9

PubMed: 24394624 ( click the link to review the publication )

Oncol Rep, 2013, 29(6):2422-30

PubMed: 23588929 ( click the link to review the publication )

Biochemistry, 2013, 53(3):462-72

PubMed: 24383815 ( click the link to review the publication )

Dig Dis Sci, 2013, 58(10):2873-80

PubMed: 23912246 ( click the link to review the publication )

PLoS One, 2013, 8(5):e61896

PubMed: 23658701 ( click the link to review the publication )

PLoS One, 2013, 8(8): e74420

PubMed: 24009772 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70804

PubMed: 23936469 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 443(2):447-52

PubMed: 24316214 ( click the link to review the publication )

Mol Biol Rep, 2013, 40(10):5645-55

PubMed: 24065522 ( click the link to review the publication )

Mol Med Rep, 2013, 7(2):642-8

PubMed: 23175237 ( click the link to review the publication )

Cell Biochem Biophys, 2013, 65(2):217-27

PubMed: 23015227 ( click the link to review the publication )

Cell Biochem Biophys, 2013, 66(3):737-46

PubMed: 23397419 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

J Clin Endocrinol Metab, 2012, 97(2):E173-82

PubMed: 22090271 ( click the link to review the publication )
Mol Cell Proteomics, 2012, 11(12):1898-912

PubMed: 23001822 ( click the link to review the publication )

J Biol Chem, 2012, 286(43):37389-98

PubMed: 21908616 ( click the link to review the publication )

Expert Opin Inv Drugs, 2012, 21(11):1597-606

PubMed: ( click the link to review the publication )

Mol Carcinog, 2012, 52(9):667-75

PubMed: 22488590 ( click the link to review the publication )

Surgery, 2012, 152(6):1218-24

PubMed: 23158188 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(11):1009-17

PubMed: 22825337 ( click the link to review the publication )

PLoS Biol, 2011, 9(9):e1001148

PubMed: 21931533 ( click the link to review the publication )

Cancer Lett, 2011, 310(1):118-28

PubMed: 21775054 ( click the link to review the publication )

J Pharmacol Exp Ther, 2011, 336(3):866-73

PubMed: 21148684 ( click the link to review the publication )

Radiat Oncol, 2011, 6:39

PubMed: 21496273 ( click the link to review the publication )

Cancer Res, 2010, 70(22):9106-17

PubMed: 21062988 ( click the link to review the publication )

Brit J Pharmacol, 2010, 160(2):355-66

PubMed: 20423345 ( click the link to review the publication )

Cytotechnology, 2010, 62(5):449-60

PubMed: 20842425 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Targets

Akt ^[1]
(MM.1S cells)

4.7 μM

In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. ^[1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. ^[2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. ^[3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
T24 BC	MULGeY5kfGmxbjDBd5NigQ>?	NH\pNngxNjVxMT:yMlUh\|ryP	NFrzZmw{KGh?	MkX5doVlfWOnczD0bIUh[mG\|YXygR2IhfHm{b4PpcoUheGixc4Doc5J6dGG2aX;uJIxmfmWuczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M2PwOlI3ODl5OEez
T24 BC	MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MYqwMlUwOS9{LkWg{txO	NYDZcGVEOjRiaB?=	Mke4[Y5p[W6lZYOgd49z[W[nbnniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliZHXjdoVie2V?	M2XYWlI3ODl5OEez
T24 BC	NYm4O4xrSXCxcITvd4l{KEG\|c4PhfS=>	MkT1Nk42KM7:TR?=	M2rNNlI1KGh?	MlXOd4Vve2m2aYrld{BDSyClZXzsd{B1dyC\|b4Lh[oVvcWJvaX7keYNm\CCjcH;weI91cWQEoB?=	Mnn6NlYxQTd6N{O=
HepG2	NWHUPGhGTnWwY4Tpc44hSXO\|YYm=	NUfWWXVMOjEEoN88US=>	MUGyOOKhcA>?	MoTjdJJw\HWlZYOgZY4hcW62ZX7z[UBkgXSxcHzhd41q[yC4YXP1c4xqgmG2aX;uJINwenKnc4DvcoRqdmdidH:gZUBvd3SjYnzlJIRqdGG2YYTpc44hd2ZidHjlJGVTKGOrc4Tldo5{	M{jWWVI2QTN2MkOy
U-87 MG	NV7veno5TnWwY4Tpc44hSXO\|YYm=	MXuyNOKh\|ryP	NWPyXVJiOjUEoHi=	MmnmbY5kemWjc3XzJIRwfWKuZT3t[Y1jemGwZTDic5Vv\CC\|dIL1Z5R2emW\|	MVSyOVk{PDJ\|Mh?=
HepG2	NXnUUXN2TnWwY4Tpc44hSXO\|YYm=	MnfrNlDDqM7:TR?=	M1zrXlYwOjRiaB?=	Mn3SbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS	MoXjNlU6OzR{M{K=
U-87 MG	M4DMTWZ2dmO2aX;uJGF{e2G7	Mon5NlDDqM7:TR?=	MV22M\|I1KGh?	MnXxbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS	NEDOS3gzPTl\|NEKzNi=>
HepG2	NE\k[5BHfW6ldHnvckBCe3OjeR?=	NWnido5KOjEEoN88US=>	NX[wOG9HPi9{NDDo	NEjNSIhl\WO{ZXHz[ZMhVEN\|LVnJJIRm\3KjZHH0bY9vyqCocn;tJFYhcA>?	MlPuNlU6OzR{M{K=
U-87 MG	NHnIVndHfW6ldHnvckBCe3OjeR?=	MVmyNOKh\|ryP	M1HveFYwOjRiaB?=	MV7pcoNz\WG\|ZYOgeIhmKGG3dH;wbIFocWNiZnz1fEAh[XRiNjDoJJdpcWynIHnubIljcXS\|IITobZMh\my3eDDheEAzPGh?	MlLFNlU6OzR{M{K=
HepG2	NWPJVXN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\IVo5sOjBxNECg{txO	Mn;3NlQwPDhiaB?=	NXK2WJg4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MmTWNlU6OzR{M{K=
U-87 MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfiNlAwPDBizszN	NUf3T45iOjRxNEigbC=>	M{XKXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	M2nCelI2QTN2MkOy
A549	NEXkPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVewMlMuOTBizszN	MWKyOE84OiCq	M4ThTolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NHr6So8zPTZ7N{i5PS=>
H460	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVewMlMuOTBizszN	M{PMS\|I1Nzd{IHi=	NI\JXndqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NFLBUFQzPTZ7N{i5PS=>
A549	MnjpRZBweHSxc3nzJGF{e3OjeR?=	NYDFOoI6OS9\|IN88US=>	M2PEZ\|Q5KGh?	MV;pcoR2[2W\|IHHwc5B1d3Orcx?=	MWCyOVY6Pzh7OR?=
H460	NYDkSoZQSXCxcITvd4l{KEG\|c4PhfS=>	NFTJVlQyNzNizszN	NEHEVGU1QCCq	NHzJemdqdmS3Y3XzJIFxd3C2b4Ppdy=>	NI\2c3YzPTZ7N{i5PS=>
A549	MVvGeY5kfGmxbjDBd5NigQ>?	NWTMUVFOOyEQvF2=	NIfpNGQ5KGh?	M2PtZYJtd2OtczDBT3Qh[WO2aY\heIlwdg>?	NGnhSHIzPTZ7N{i5PS=>
H460	MUHGeY5kfGmxbjDBd5NigQ>?	NIC4clI{KM7:TR?=	M2PlNFghcA>?	MX\icI9kc3NiQVvUJIFkfGm4YYTpc44>	NXns[ow1OjV4OUe4PVk>
A549	MkPlSpVv[3Srb36gRZN{[Xl?	NGi2XHE{KM7:TR?=	NVTtRYdjQCCq	NGnOcmVjdG:la4OgcXRQWkNzLDDhcoQhTVKNLV3BVGsh[WO2aY\heIlwdiClb33ibY5m\CC5aYToJG1GUy1zNkK=	MnLwNlU3QTd6OUm=
H460	NIrJbYFHfW6ldHnvckBCe3OjeR?=	NWHmWpFzOyEQvF2=	NWW1[YxHQCCq	M{m3RoJtd2OtczDtWG9TSzFuIHHu[EBGWktvTVHQT{Bi[3SrdnH0bY9vKGOxbXLpcoVlKHerdHigUWVMNTF4Mh?=	NHjQPJQzPTZ7N{i5PS=>
RMG1	NWPFRXROS2WubDDWbYFjcWyrdImgRZN{[Xl?	MX:xMVMxKM7:TR?=	M{CwfVczKGh?	NWDMZ5E5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NVLKblQ3OjV3MUmxOFg>
RMG2	M1\EPGNmdGxiVnnhZoltcXS7IFHzd4F6	M2TJZVEuOzBizszN	MXy3NkBp	NXLWU3VO\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	M1HYRlI2PTF7MUS4
KOC7C	NVvob4ZOS2WubDDWbYFjcWyrdImgRZN{[Xl?	NH62SpYyNTNyIN88US=>	NFrwNlQ4OiCq	M4Gzc4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MYWyOVUyQTF2OB?=
HAC2	NXvKOWQ3S2WubDDWbYFjcWyrdImgRZN{[Xl?	NHrOTGoyNTNyIN88US=>	MYG3NkBp	M2r3[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M3PzNFI2PTF7MUS4
RMG2	MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NGnpSmQyNTNyIN88US=>	Mn3iOFghcA>?	MkK4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MYWyOVUyQTF2OB?=
OVISE	M3;mdWNmdGxiVnnhZoltcXS7IFHzd4F6	NV7ib2VOOS1\|MDFOwG0>	MYm0PEBp	Mnf6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NX3nWW5TOjV3MUmxOFg>
SKOV3	MlzxR4VtdCCYaXHibYxqfHliQYPzZZk>	NEPn[o0yNTNyIN88US=>	M1;QfFQ5KGh?	MkT6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NFXjb3kzPTVzOUG0PC=>
A2780	MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MWexMVMxKM7:TR?=	Mn;3OFghcA>?	NWTpRpFw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	M{fsU\|I2PTF7MUS4
RMG1	NGT3elRCeG:ydH;zbZMhSXO\|c3H5	MX6zNEDPxE1?	M4\2OVI1KGh?	NHPFbIdqdmS3Y3XzJIFxd3C2b4Ppdy=>	MY[yOVUyQTF2OB?=
RMG2	Mo\LRZBweHSxc3nzJGF{e3OjeR?=	MoDKN\|Ah\|ryP	NFnDbWMzPCCq	MmDabY5lfWOnczDhdI9xfG:\|aYO=	M1XwTFI2PTF7MUS4
HCC1806	MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXywMVExKM7:TR?=	M2\DbVQ5KGh?	NUfpe4ZXTUN3ME2yMlg16oDLwsJihKkxNjB5IN88US=>	MXqyOVI6OzV5Nh?=
MDA-MB-231	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fP[lAuOTBizszN	Mm\rOFghcA>?	MlPJSWM2OD1zLkGz5qCKyrIkgJmwMlA4KM7:TR?=	NVzmdXBXOjV{OUO1O\|Y>
GL-1	M3zFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDNZlYxNjIkgKOxNFDjiIoQvF2=	M1O4flQ5KGh?	M3v2fWlEPTB;OT65NUDPxE1?	M13qWlI1QDhzNUC4
CLBL-1	NXz0eWR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVqwMlHjiJNzMEFihKnPxE1?	NFyyOI01QCCq	M2G2TWlEPTB;M{OuNEDPxE1?	MYeyOFg5OTVyOB?=
UL-1	NInJe\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\1dnZ1OC5z4pETNVAx6oDLzszN	M2PjT\|Q5KGh?	M3zDSmlEPTB;Nz6wNUDPxE1?	NVf4R\|J[OjR6OEG1NFg>
Ema	Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvtNE4y6oDVMUCw5qCK\|ryP	MUW0PEBp	MmD6TWM2OD13OD63JO69VQ>?	MX[yOFg5OTVyOB?=
PANC-1	Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17qPFAuOjVizszN	NViwd2hRPzJiaB?=	NF\HdndqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NV;1UG9xOjR3MUm3OVE>
MIA	MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPy[WsxNTJ3IN88US=>	MXW3NkBp	MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MUmyOFUyQTd3MR?=
AsPC-1	NUPHWJJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TNNlAuOjVizszN	M{DtNFczKGh?	NG\RbXFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MXKyOFUyQTd3MR?=
PANC-1	NFv2SplHfW6ldHnvckBCe3OjeR?=	MUiwMlUh\|ryP	MWSyOEBp	MY\pcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM\|IheGixc4Doc5J6dGG2aX;uxsA>	MVGyOFUyQTd3MR?=
MIA	Ml3VSpVv[3Srb36gRZN{[Xl?	NY\vNlRROC53IN88US=>	M3GxW\|I1KGh?	M1XrTolvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb\|EwOiCyaH;zdIhwenmuYYTpc47DqA>?	NXnJVXR1OjR3MUm3OVE>
AsPC-1	NVuzWHN7TnWwY4Tpc44hSXO\|YYm=	M1TuRVAvPSEQvF2=	M1GyelI1KGh?	M4XyW4lvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb\|EwOiCyaH;zdIhwenmuYYTpc47DqA>?	MYSyOFUyQTd3MR?=
U87MG	NVjDdlhSS2WubDDWbYFjcWyrdImgRZN{[Xl?	MlS5NE0zPSEQvF2=	M2PCW\|I1NTl4IHi=	NY\OOpE6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	NEThNWkzPDB4NUWyNi=>
SGC7901	M3:4cWZ2dmO2aX;uJGF{e2G7	NHjae4kxNjd3L{GwxsDPxE1?	M3nle\|Q5KGh?	NViwV\|RC\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh	NYTUU3pGOjN7MUKyOFY>
MGC803	M1P2cmZ2dmO2aX;uJGF{e2G7	MYmwMlc2NzFywrFOwG0>	M2PpUlQ5yqCq	MWHk[YNz\WG\|ZYOgdE1Cc3RiKGPldkA1PzNrLDDwMWdUUzQQsjCoV4VzKDlrLDDhcoQhSy2PWVOgcIV3\Wy\|wrC=	M1WzdVI{QTF{MkS2
TykNu	NYqwUFhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MULJR\|UxRTNwNTFOwG0>	NYLrTHFuOjN6N{ewNVI>
TykNuR	MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUXJR\|UxRTVwNTFOwG0>	MkHlNlM5PzdyMUK=
M41	MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVnJR\|UxRTJ2Lkeg{txO	NUjGPWpFOjN6N{ewNVI>
M41R	NWnUeGJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2faVWlEPTB;MUmuPEDPxE1?	NYXkPIhpOjN6N{ewNVI>
OVCAR8	NX7tbGhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH3C[JVKSzVyPUOxMlEh\|ryP	Mk\INlM5PzdyMUK=
HeyA8	NG\mTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml[yTWM2OD1{ND6zJO69VQ>?	MnuxNlM5PzdyMUK=
A2780CP	Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEKwZ4ZKSzVyPUeuOkDPxE1?	MnH3NlM5PzdyMUK=
OVCAR5	NV\mVGJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmHiTWM2OD14Lkeg{txO	MYGyN\|g4PzBzMh?=
A2780S	NEPKTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXvJR\|UxRTF2LkWg{txO	M3fQRlI{QDd5MEGy
MCAS	MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGLOZYZKSzVyPUGyMlUh\|ryP	M2TRXVI{QDd5MEGy
NCI-H727	M36xcmNmdGxiVnnhZoltcXS7IFHzd4F6	NFHPcpoxNTFyMDFOwG0>	MmLyNlQwPzJiaB?=	M4\sUIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	M{HiNlIzPDl7NEO3
GOT1	NWDjfIlkS2WubDDWbYFjcWyrdImgRZN{[Xl?	NWjjeFd6OC1zMECg{txO	MorQNlQwPzJiaB?=	NHjtOW9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	MoPMNlI1QTl2M{e=
BON1	NYDESGVnS2WubDDWbYFjcWyrdImgRZN{[Xl?	M3zlRVAuOTByIN88US=>	MVuyOE84OiCq	MUPk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NW\NVJZCOjJ2OUm0N\|c>
BON1	M1PqZmFxd3C2b4Ppd{BCe3O\|YYm=	NVj4VI9pOC1zMDFOwG0>	MYeyOEBp	NH\UeldqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	MWOyNlQ6QTR\|Nx?=
BON1	MofPSpVv[3Srb36gRZN{[Xl?	NE\t[\|g4NjVxMUCg{txO	NVLRTWlJQCCq	NEGyOpJl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhfGinIHHueIku[XCxcITveIlkKHC{b4TlbY5{KEKFTEKgZY5lKEKlbD3YUC=>	MkHPNlI1QTl2M{e=
Kasumi-1	NYr5UWRzS2WubDDWbYFjcWyrdImgRZN{[Xl?	MmnhNE0zOCEQvF2=	MXGyOE81QCCq	MnOz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	M{DqNVIzPDB5MkK4
HL-60	MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mn3rNE0zOCEQvF2=	NEHIfVIzPC92ODDo	MoHS[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	MUGyNlQxPzJ{OB?=
Kasumi-1	NXHXUIZ7SXCxcITvd4l{KEG\|c4PhfS=>	M4P3SFExKM7:TR?=	MnHmNlQhcA>?	NX\JUGo1cW6mdXPld{BieG:ydH;zbZM>	NV;NcFV3OjJ2MEeyNlg>
HL-60	Ml\XRZBweHSxc3nzJGF{e3OjeR?=	M{LJU\|ExKM7:TR?=	MYKyOEBp	MmHtbY5lfWOnczDhdI9xfG:\|aYO=	MYSyNlQxPzJ{OB?=
Kasumi-1	M4XRPGZ2dmO2aX;uJGF{e2G7	NEHSSYszNjVxNT:xNEDPxE1?	Mn3jNlQhcA>?	NVHD[3p3\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy\|wrDkc5NmNWSncHXu[IVvfGy7	M{DmXFIzPDB5MkK4
HL-60	MVrGeY5kfGmxbjDBd5NigQ>?	MV:yMlUwPS9zMDFOwG0>	MojSNlQhcA>?	Mo\3[IVkemWjc3XzJGFsfCCjbnSgdE1Cc3RibHX2[Yx{yqCmb4PlMYRmeGWwZHXueIx6	NFr3coszOjRyN{KyPC=>
Kasumi-1	MoOySpVv[3Srb36gRZN{[Xl?	M4\lOlIvPS93L{GwJO69VQ>?	NFTNOWozPCCq	NWT5UmlDcW6mdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFrOT\|EwOiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MlviNlI1ODd{Mki=
HL-60	MY\GeY5kfGmxbjDBd5NigQ>?	NWjkWIFCOi53L{WvNVAh\|ryP	MUiyOEBp	NHzsT3BqdmS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiSl7LNU8zKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NFLsWnQzOjRyN{KyPC=>
K562	MWnGeY5kfGmxbjDBd5NigQ>?	NITyN4ozOCEQvF2=	MXG0PEBp	NVviboROcW6mdXPld{BifXSxcHjh[5nDqA>?	NGPzN3kzOjRyN{KyPC=>
OCUT1	M1rke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmO5NE4yNTNizszN	MUi1JIQ>	MnvybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NYDLT3VJOjJyOUCyO\|E>
K1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jtOlAvOS1\|IN88US=>	NEP4ZmQ2KGR?	NXGxZldbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MlLkNlIxQTB{N{G=
OCUT1	NWjWT3l2TnWwY4Tpc44hSXO\|YYm=	MYmzJO69dQ>?	NWHJTIVXOjRiaB?=	MmfKZ4F2e2W\|IHGg[JJidWG2aXOgbY5kemWjc3WgbY4hTzJxTTDwbIF{\Q>?	NXXDS3Q5OjJyOUCyO\|E>
CaOV3	NXy0c2FmS2WubDDWbYFjcWyrdImgRZN{[Xl?	Mn3HNU82NzFyIN88US=>	MljrOFghcA>?	MX3k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJiY3;0doVifGWmIIfpeIgheGGlbHn0ZZhmdA>?	MoHPNlE4PzVyNUS=
SKOV3	MVrDfZRwfG:6aXPpeJkhSXO\|YYm=	MX21JO69VQ>?	M4LCSFQ5KGh?	M4XYWYVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA>	MXSyNVc4PTB3NB?=
A2780	NILCXZlEgXSxdH;4bYNqfHliQYPzZZk>	M2XJR\|Uh\|ryP	MnzKOFghcA>?	M1\XUYVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA>	M{K1WlIyPzd3MEW0
HT-29	NWLUSFlSS3m2b4TvfIlkcXS7IFHzd4F6	M2D0ZlUh\|ryP	M2fIZVQ5KGh?	M{\McIVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA>	MYmyNVc4PTB3NB?=
A498	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XaVFAuPDBizszN	NIP6UXI4OiCq	NGD2NI5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M2rCOFIyPjR2MEWw
CAKI-1	MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\uUVAuPDBizszN	NXjPZXlSPzJiaB?=	NI\ic5BKSzVyfkGwJO69VQ>?	MX2yNVY1PDB3MB?=
769-P	MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWGwMVQxKM7:TR?=	NVjqW4lOPzJiaB?=	MV;JR\|UxhjVvMUCg{txO	MkHJNlE3PDRyNUC=
786-0	NWHnR5VsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXoNE01OCEQvF2=	MVW3NkBp	M163SGlEPTC-NTFOwG0>	NFrqRWwzOTZ2NEC1NC=>
786-O	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjq[mIxNTJyIN88US=>	MYO3NkBp	MmXBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MXmyNVY1PDB3MB?=
CAKI-1	MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXqwMVIxKM7:TR?=	MWm3NkBp	NUP2PXZQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MX2yNVY1PDB3MB?=
769-P	NIewVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYSwMVIxKM7:TR?=	NV7JUHFsPzJiaB?=	MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	Mk\MNlE3PDRyNUC=
A498	MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzJSot3OC1{MDFOwG0>	NVv6fHRMPzJiaB?=	M3OzUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MnT1NlE3PDRyNUC=
CWR22RV1	NEDwcpBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NHnOcW8yOCEQvF2=	M2Pkc\|I1KGh?	MlvabY5kemWjc3XzJJNmdnOrdHn2bZR6KG:oIHj1cYFvKEOZUkKyVnYyKGOnbHzzJJRwKHKjZHnheIlwdg>?	M2\idlIyPDl4Mkez
CWR22RV1	NF;5O5ZCeG:ydH;zbZMhSXO\|c3H5	NI\3U2YyOCEQvF2=	MlTvNlQhcA>?	NYTXPGJM\W6qYX7j[ZMhemGmaXH0bY9vKGmwZIXj[YQh[XCxcITvd4l{	NHH1SHczOTR7NkK3Ny=>
CWR22RV1	NUHnNJY6TnWwY4Tpc44hSXO\|YYm=	MVS1JO69VQ>?	NGLkboczPCCq	MWPy[YR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDBb5Qhe2mpbnnmbYNidnSueR?=	MlLMNlE1QTZ{N{O=
HepG2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LZPFUwOTBxMkCvOFAh\|ryP	M3nrWVI1NzR6L{eyJIg>	MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M1zuc\|IxQDR{NEK1
Bel-7402	NEXteppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LyfVUwOTBxMkCvOFAh\|ryP	MmjJNlQwPDhxN{KgbC=>	MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MoDnNlA5PDJ2MkW=
HepG2	Moi1SpVv[3Srb36gRZN{[Xl?	NIH0cHM2NzFyL{KwJO69VQ>?	MX:yOEBp	NYPu[3hFemW\|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPl	NWe0NZE3OjB6NEK0NlU>
Bel-7402	M1faeGZ2dmO2aX;uJGF{e2G7	MWm1M\|ExNzJyIN88US=>	NGrZc4wzPCCq	MXXy[ZN2dHS\|IHnuJJRp\SCjY3P1cZVt[XSrb36gc4Yh[2WubDDueY1j\XJiaX6geIhmKEd{L12gdIhie2V?	MXKyNFg1OjR{NR?=
HepG2	Ml\0RZBweHSxc3nzJGF{e3OjeR?=	M3PJblUwOTBxMkCg{txO	NGfnbHQzPC92ODDo	NUnNbm1ycW6mdXPld{BieG:ydH;zbZMh[XRidHjlJIxwdmdvdHnt[UBmgHCxc4Xy[S=>	Moq0NlA5PDJ2MkW=
Bel-7402	NFfEfZBCeG:ydH;zbZMhSXO\|c3H5	NWPOeXRQPS9zMD:yNEDPxE1?	NEHM[mQzPC92ODDo	MnXBbY5lfWOnczDhdI9xfG:\|aYOgZZQhfGinIHzvcocufGmvZTDlfJBwe3W{ZR?=	Mn62NlA5PDJ2MkW=
OAW-42	M4fPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYSyR\|U1OC12MDFOwG0>	NFztVYg4OsLiaB?=	MYjJR\|UxhjFyIN88UUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MkXmNlA1ODV{OU[=
PA-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUGwMVQxKM7:TR?=	MX63NuKhcA>?	M3zhXGlEPTC-MkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MWOyNFQxPTJ7Nh?=
SKOV3	MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n5S\|AuPDBizszN	MWW3NuKhcA>?	Ml3XTWM2OH5\|MDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MWiyNFQxPTJ7Nh?=
A2780	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPxZnExNTJyIN88US=>	M1TGV\|Q5Nzd{IHi=	M3;6dWlEPTEEoE5CpFPDqM7:bR?=	M2DXWlIxPDB3Mkm2
A2780cis	NIDkOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVqwMVIxKM7:TR?=	M1ux[\|Q5Nzd{IHi=	NF\zbm1KSzVywrC9xsA3yqEQvH2=	NHLDPGIzODRyNUK5Oi=>
SKW6.4	M{HuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfnXGkzNTFywrFOwG0>	MUG0POKhcA>?	M{Lac4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NUGxbW1GOjBzM{C5OlA>
MAVER	NFnrdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTxOFdDOi1zMNMg{txO	MYi0POKhcA>?	NHP1RZRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NXvzXXR4OjBzM{C5OlA>
BJAB	NYrXOIJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPDdIEzNTFywrFOwG0>	M1\DW\|Q5yqCq	NVvxe4k1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NXnuS4dvOjBzM{C5OlA>
OCI	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnHSVVZOi1zMNMg{txO	NITEPYc1QMLiaB?=	MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NXTTVo15OjBzM{C5OlA>
MOLM	M1HRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYmyMVExyqEQvF2=	NX7sS5ZSPDkEoHi=	NY[1TpBUcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MYOyNFE{ODl4MB?=
HL-60	NIqxTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfKNk0yOMLizszN	MYK0POKhcA>?	M{m5ZYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	M4\rbFIxOTNyOU[w
SKW6.4	Mk\zRZBweHSxc3nzJGF{e3OjeR?=	M{XNZlExyqEQvF2=	M2fJNlI1NzR6IHi=	M{jIVolv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm=	MnjsNlAyOzB7NkC=
MAVER	MVHBdI9xfG:\|aYOgRZN{e2G7	MmLBNVDDqM7:TR?=	MkDDNlQwPDhiaB?=	NFrlb3pqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	M{LEe\|IxOTNyOU[w
BJAB	MnH0RZBweHSxc3nzJGF{e3OjeR?=	M1HHbFExyqEQvF2=	NFHKS4UzPC92ODDo	M4faN4lv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm=	MlvZNlAyOzB7NkC=
OCI	NWXTbXVpSXCxcITvd4l{KEG\|c4PhfS=>	NWfrenZbOTEEoN88US=>	NWC2WW5{OjRxNEigbC=>	Mo[xbY5lfWOnczDhdI9xfG:\|aYOgeIlu\S2mZYDlcoRmdnSueR?=	MXGyNFE{ODl4MB?=
MOLM	NIPQNW9CeG:ydH;zbZMhSXO\|c3H5	M4jxUFExyqEQvF2=	MUeyOE81QCCq	NF\yO\|hqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	NUju[mZoOjBzM{C5OlA>
HL-60	NH3rXVhCeG:ydH;zbZMhSXO\|c3H5	NX:3N2gxOTEEoN88US=>	MkfmNlQwPDhiaB?=	Mm[wbY5lfWOnczDhdI9xfG:\|aYOgeIlu\S2mZYDlcoRmdnSueR?=	Mk\ZNlAyOzB7NkC=

... Click to View More Cell Line Experimental Data

In vivo

Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. ^[2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. ^[3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. ^[5]

Protocol

Kinase Assay:^[3]	+ Expand Akt kinase assay: MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:^[2]	+ Expand Cell lines: Human glioma cell lines Concentrations: 0, 15, 30 and 45 μM Incubation Time: 48 hours Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader. (Only for Reference)
Animal Research:^[3]	+ Expand Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old). Formulation: 0.9% NaCl solution Dosages: 250 mg/kg/wk or 36 mg/kg/d Administration: Oral gavage (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	Ethanol	15 mg/mL (32.49 mM)
	Water	8 mg/mL (17.32 mM)
	DMSO	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Perifosine (KRX-0401) SDF

Molecular Weight	461.66
Formula	C₂₅H₅₂NO₄P
CAS No.	157716-52-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC639966

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01224730	Completed	Drug: perifosine	Cancer	AEterna Zentaris	January 24 2012	Phase 1
NCT01049841	Completed	Drug: perifosine + temsirolimus	Pediatric Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|NATL COMP CA NETWORK\|Pfizer\|AEterna Zentaris	January 2010	Phase 1
NCT01048580	Completed	Drug: Perifosine\|Drug: Capecitabine	Colon Cancer	AEterna Zentaris\|SCRI Development Innovations LLC	October 2009	Phase 1
NCT00776867	Completed	Drug: perifosine	Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|AEterna Zentaris	October 2008	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Selective Akt Inhibitor

CCT128930 : AKT2-selective, IC50=6 nM.
Most Potent Akt Inhibitor

AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.
Akt Inhibitor in Clinical Trial

Ipatasertib (GDC-0068) : Phase II for Prostate Cancer and Gastric Cancer.
Newest Akt Inhibitor

AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

Afuresertib (GSK2110183) ^New

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
AT13148 ^New

AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
SC79 ^New

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
Capivasertib (AZD5363)

AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Ipatasertib (GDC-0068)

Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.
GSK690693

GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.
A-674563

A-674563 is an Akt1 inhibitor with K_i of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.
Triciribine

Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Honokiol

Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Perifosine (KRX-0401)

Cited by 85 Publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Perifosine (KRX-0401) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Choose Your Country or Region

By Signaling Pathways

By product type

Perifosine (KRX-0401)

Cited by 85 Publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Perifosine (KRX-0401) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)